- Activity pressure is positive on the latest completed week.
ALT
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Altimmune Inc · Healthcare · Biotechnology
Latest close
2.77 USD
-3.5%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -20.6% below the Trend Line and sits at 5.4% of its 52-week range. The latest completed week returned -3.5%, after a -1.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 58/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.
Setup score
26
out of 100
Latest Close
2.77 USD
24 Jul 2026
1W Return
-3.5%
latest completed week
4W Return
-1.8%
short-term follow-through
12W Return
-1.8%
quarterly tape
Trend Breadth
11.5%
6 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.5%
Latest completed week; four-week move -1.8%.
Indicator stack
6/67
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Volatility
58/100 conviction; expected move 8.1%.
News sentiment
55/100
65 relevant articles in the latest sentiment read.
Event risk
13d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -20.6% below the Trend Line and sits at 5.4% of its 52-week range. The latest completed week returned -3.5%, after a -1.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0312-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -1.8% over four weeks, -1.8% over 12 weeks, and -32.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.27Latest activity-pressure read.
Pressure change156.4%Four-week change in activity pressure.
Leadership-32.73Latest relative-leadership reading.
RS change10.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -15.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- -41519.4% Gross profit retained from each unit of revenue.
- Operating margin
- -245494.4% Operating profit retained from revenue.
- Free-cash-flow margin
- -198902.8% Free cash flow generated from revenue.
- Return on invested capital
- -29.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 80.0% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -40.5% Net share repurchases relative to market value.
- Shareholder yield
- -40.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
ALT shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of 0.09, expected move of 8.1%, and Sharemaestro trend signal inactive.
Conviction58/100
Expected move8.1%
Put/call volume0.09
Insider activity8 / 0
8 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 65 relevant articles.
21 positive · 36 neutral · 8 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move8.1%Nearest-chain priced movement where available.
52-week drawdown-57.0%Distance below the 52-week high.
13-week volatility6.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher9 of 2617 weeks finished lower.
Best week+12.1%Week of 3 Jul.
Worst week-18.6%Week of 24 Apr.
Latest week-3.5%Week of 24 Jul.
Shape of recent returns
Strong gains6
Modest gains3
Flat weeks0
Modest losses8
Sharp losses9
Recent vol6.5%13-week weekly-return volatility.
Base vol9.1%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -6.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape24/100
Trend, activity pressure, participation, and risk combine to a 24/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.03; No reversal markers Factors64/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 95; Small Cap Core rank 47 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options37/100ALT shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of 0.09, expected move of 8.1%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 8.1% Sentiment55/100Weighted news tone is neutral across 65 relevant articles.
H.C. Wainwright reiterates Altimmune stock rating on trial results Insiders8 / 08 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 2.77 USD | -3.5% | 3.49 USD | 5.51 USD | 0.27 | -32.73 | 10.4M | Off |
| 17 Jul 2026 | 2.87 USD | -5.9% | 3.53 USD | 5.51 USD | 0.34 | -32.10 | 14.6M | Off |
| 10 Jul 2026 | 3.05 USD | -3.5% | 3.56 USD | 5.52 USD | 0.22 | -31.53 | 18.4M | Off |
| 3 Jul 2026 | 3.16 USD | 12.1% | 3.63 USD | 5.52 USD | -0.08 | -28.52 | 20.0M | Off |
| 26 Jun 2026 | 2.82 USD | 4.4% | 3.70 USD | 5.52 USD | -0.48 | -36.48 | 33.4M | Off |
| 19 Jun 2026 | 2.70 USD | 3.4% | 3.79 USD | 5.52 USD | -0.74 | -42.34 | 21.7M | Off |
| 12 Jun 2026 | 2.61 USD | -3.7% | 3.86 USD | 5.53 USD | -0.96 | -44.42 | 14.1M | Off |
| 5 Jun 2026 | 2.71 USD | -11.1% | 3.91 USD | 5.54 USD | -1.08 | -42.58 | 14.4M | Off |
| 29 May 2026 | 3.05 USD | 5.2% | 3.95 USD | 5.55 USD | -1.10 | -39.47 | 11.3M | Off |
| 22 May 2026 | 2.90 USD | 1.8% | 3.99 USD | 5.56 USD | -1.16 | -41.83 | 13.3M | Off |
| 15 May 2026 | 2.85 USD | -7.8% | 4.02 USD | 5.56 USD | -1.05 | -43.27 | 13.6M | Off |
| 8 May 2026 | 3.09 USD | 9.6% | 4.05 USD | 5.57 USD | -0.93 | -39.79 | 19.3M | Off |
| 1 May 2026 | 2.82 USD | -1.1% | 4.08 USD | 5.59 USD | -0.89 | -43.11 | 26.3M | Off |
| 24 Apr 2026 | 2.85 USD | -18.6% | 4.12 USD | 5.60 USD | -0.87 | -42.76 | 53.6M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.